Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR2 | P50052 | 4/20 | 0.53 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.53 |
| ▸ | C5AR1 | P21730 | 2/20 | 0.50 |
| ▸ | MC4R | P32245 | 1/20 | 0.49 |
| ▸ | F2 | P00734 | 4/20 | 0.49 |
| ▸ | NTSR1 | P30989 | 5/20 | 0.48 |
| ▸ | NTSR2 | O95665 | 3/20 | 0.48 |
| ▸ | SORT1 | Q99523 | 2/20 | 0.47 |
| ▸ | EPHA2 | P29317 | 2/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.46 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.46 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22197758 | 0.96 | C5AR1 (0.50) | AGTR2AGTR1C5AR1MC4RF2 | |
| SCHEMBL22912571 | 0.95 | C5AR1 (0.54) | AGTR2AGTR1C5AR1MC4RF2 | |
| SCHEMBL22197757 | 0.92 | C5AR1 (0.51) | AGTR2AGTR1C5AR1MC4RF2 | |
| Talfirastide SCHEMBL15926158 | 0.92 | AGTR1 (0.59) | AGTR2AGTR1C5AR1MC4RF2 | |
| SCHEMBL29701258 | 0.92 | AGTR2 (0.55) | AGTR2AGTR1C5AR1MC4RF2 | |
| SCHEMBL7052378 | 0.89 | AGTR2 (0.65) | AGTR2AGTR1C5AR1F2NTSR1 | |
| SCHEMBL9510693 | 0.88 | AGTR1 (0.60) | AGTR2AGTR1C5AR1MC4RF2 | |
| SCHEMBL29701256 | 0.88 | AGTR2 (0.65) | AGTR2AGTR1C5AR1F2NTSR1 | |
| SCHEMBL29972916 | 0.88 | AGTR1 (0.62) | AGTR2AGTR1C5AR1F2NTSR1 | |
| Angiotensin Ii SCHEMBL22125774 | 0.88 | AGTR2 (0.69) | AGTR2AGTR1C5AR1F2NTSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210024578-A1 | ANGIOTENSIN-(1-7) ANALOGS AND METHODS RELATING THERETO | UNIVERSITY COLLEGE DUBLIN (IE) | 2021-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210024578-A1 | ANGIOTENSIN-(1-7) ANALOGS AND METHODS RELATING THERETO | ACE, AGT, ACE2 | AGTR2 6/4885AGTR1 4/4885C5AR1 306/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.